teamLab Planets TOKYO Reveals Entirety of the Newly Expanded Area, Featuring “Catching and Collecting Forest” and “Athletics Forest”. Opening January 22
21.1.2025 19:00:00 EET | Business Wire | Press release
A new large-scale Athletics Forest and more artworks will open at teamLab Planets TOKYO DMM in Toyosu, Tokyo (teamLab Planets) on January 22, 2025.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250120453018/en/
teamLab, Catching and Collecting Extinct Forest (c) teamLab - There are various extinct animals that live in this Extinct Forest. When you move close to the animals or touch them, they will run away or turn to face you.
teamLab Planets increases its area by 1.5 times, creating an extensive new space to introduce teamLab’s educational projects. The new additions include Athletics Forest, a complex, multi-dimensional creative athletic space; Catching and Collecting Extinct Forest where visitors can capture and study extinct animals; and Future Park, a collaborative space for co-creation. Over 20 new artworks will be exhibited.
In addition, new spaces have been introduced to the museum, such as the Orchid Glass House, where visitors can enjoy tea and drinks surrounded by orchids; the Living Art Store, where visitors can take home regrown orchids; and Sketch Factory, where visitors’ drawings created within the artwork space are transformed into original products to take home. The outdoor area featuring the Black Emptiness Table, where visitors can enjoy Vegan Ramen UZU Tokyo, will also undergo a major renovation.
Tickets through March 2025 are now available on the official website.
teamLab Planets TOKYO DMM
https://www.teamlab.art/e/planets/
#teamLabPlanets
July 7, 2018 - End of 2027
Toyosu, Tokyo (teamLab Planets TOKYO, Toyosu 6-1-16, Koto-ku, Tokyo)
Highlight Video
https://youtu.be/F7nODEETR4s
Press kit
https://www.dropbox.com/sh/ir7d2aui794eo6z/AAChbzX5wPsQm8cgkQ2ViFD4a?dl=0
View source version on businesswire.com: https://www.businesswire.com/news/home/20250120453018/en/
Contacts
teamLab Planets PR Department
E-MAIL: pr-info@planets.art
For interview enquiries: https://forms.gle/fAtnDKLpQKFME6XR9 -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fforms.gle%2FfA
tnDKLpQKFME6XR9&esheet=54183215&newsitemid=20250120453018&lan=en-US&anchor=https
%3A%2F%2Fforms.gle%2FfAtnDKLpQKFME6XR9&index=7&md5=5ee9967d2ddfb6f1a9b18144972ae
6f9
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives European Union Approval for Restylane ® Shaype™: the First-and-Only Bone-Mimicking Hyaluronic Acid Injectable for Facial Shaping11.8.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD) today announced that Restylane Shaype has been approved in the EU under the Medical Device Regulation for temporary augmentation of the chin region. Engineered for deep injection to build and shape on bone, Restylane Shaype delivers a unique bone-mimicking effect, enabling immediate, natural-looking structural enhancement in the lower face without surgery.1-3 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260810880899/en/ The lower face plays a pivotal role in overall facial balance, influencing proportions and profile.2 This region is an increasing area of concern for patients, with around one in four people expressing concerns related to lower face sagging and chin shape.5 When asked about their facial priorities, a third of people pointed out issues with their chin shape – a key contributor to facial definition and structural harmony.5 Genetic factors and age-related changes can lead to reduced chin d
Stonebranch is Again Named a Leader in the 2026 Gartner ® Magic Quadrant ™ for Service Orchestration and Automation Platforms (SOAPs)10.8.2026 18:00:00 EEST | Press release
Stonebranch, a leading provider of service orchestration and automation solutions, today announced that it has once again been positioned by Gartner as a Leader in the Magic Quadrant for Service Orchestration and Automation Platforms (SOAPs) for its offering, Universal Automation Center™ (UAC).1 “We’re pleased to be recognized as a Leader for the third year in a row,” said Giuseppe Damiani, CEO at Stonebranch. “To us, this recognition reflects our advancements in helping enterprises orchestrate increasingly complex IT operations with confidence. As organizations modernize their automation strategies and adopt AI, UAC provides the centralized orchestration control plane required to unify traditional automation with AI models and agentic systems. With built-in capabilities like Robi AI, UAC’s agentic copilot, we’re making it easier than ever for teams to build, manage, and optimize automation at enterprise scale.” Stonebranch UAC helps organizations unify, manage, and scale automation ac
Frontgrade Expands Huntsville Presence with Advanced R&D Center Supporting Next-Generation Space and Defense Missions10.8.2026 17:09:00 EEST | Press release
Frontgrade Technologies ("Frontgrade"), a leading provider of mission-critical electronics and integrated technologies, today announced the opening of its eighth U.S. location in Huntsville, Alabama. Located in Cummings Research Park, the new Advanced Research & Development Center will accelerate the development of next-generation mission processing technologies supporting critical space, defense, intelligence, and national security missions. The Huntsville center expands Frontgrade's engineering capabilities while placing research teams closer to customers, government organizations, industry partners, and leading academic institutions. By working within one of the nation's premier aerospace and defense ecosystems, Frontgrade will accelerate technology development, strengthen customer collaboration, and help deliver mission-ready capabilities faster. “Bringing Frontgrade’s capabilities to Huntsville is a meaningful milestone for me, both personally and professionally. For decades, this
Brightfin Appoints Preeti Shukla as Chief Product and AI Officer10.8.2026 16:00:00 EEST | Press release
Brightfin, the only IT Financial Management (ITFM) and Technology Expense Management solution built natively on ServiceNow, today announced the appointment of Preeti Shukla as Chief Product and AI Officer (CPAIO). In this newly created role, Shukla will lead product strategy and artificial intelligence across the Brightfin platform, advancing the company's mission to make every technology decision grounded in financial truth, operational clarity, and intelligent automation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260810283143/en/ Preeti Shukla, CPAIO of Brightfin Shukla brings two decades of experience building and scaling customer-facing, enterprise-grade B2B SaaS, fintech, and marketplace products across Fortune 100 companies and high-growth startups, including leadership roles at Workday and Oracle. A recognized authority on applied AI, she is a Gartner-recognized thought leader and author on AI SaaS and product en
BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration10.8.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, and Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced a multi-part collaboration including: a clinical collaboration to evaluate drug combinations incorporating select clinical-stage oncology assets from BeOne with any of Revolution Medicines’ four clinical RAS(ON) inhibitors, and a separate regional rights agreement granting BeOne exclusive development and commercialization rights to these Revolution Medicines assets in select Asian markets. Clinical collaboration will explore potential targeted combination approaches for patients with RAS-addicted cancers Potential drug combinations for development as part of the clinical collaboration will include certain BeOne assets and Revolution Medicines’ four clinical RAS(ON) inhibitors: daraxonrasib, a RAS(ON) multi-selective inhibitor; zo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom